DERM earnings analysis
What we found in DERM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 revenue was $17.839 million and diluted EPS was $(0.01), with revenue missing consensus by approximately 3.2% but EPS beating the $0.02 estimate by $0.01. The supplied 10-Q extract does not include the financial statements or MD&A, so gross margin, operating margin, segment performance, cash flow, free cash flow, balance-sheet changes, and quantitative outlook cannot be reliably assessed. Risk factors were incorporated by reference to the 2025 Form 10-K, with no specific new risk-factor changes identified.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Missed Consensus
- Q2 revenue was $17.839 million, below the $18.4372 million consensus estimate by approximately 3.2%.
- EPS Beat Consensus
- Diluted EPS was $(0.01), better than the $(0.02) consensus estimate by $0.01 per share.
- Disclosure Controls Effective
- The company states that its disclosure controls and procedures were effective as of June 30, 2026.
- No Material Control Changes
- No material change in internal control over financial reporting occurred during the quarter, according to management.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Prior-Year Risks Remain Applicable
- The company states that the risk factors disclosed in its 2025 Form 10-K continue to apply and may materially affect its business, financial condition, or results of operations; no newly quantified risk-factor change was provided in this 10-Q.
- Potential Litigation Exposure
- No material legal proceedings are pending other than routine actions, administrative proceedings, and other actions; however, the company notes that insured and uninsured litigation may arise in the ordinary course.
- Limited Liquidity Disclosure
- The filing provides no quantitative balance-sheet or cash-flow detail in the supplied extract, limiting assessment of liquidity, debt, inventory, receivables, and operating cash-flow risk.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.01
What they said about what is next.
The 10-Q does not provide explicit numeric revenue or EPS guidance; no forward quantitative outlook was identified.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Journey Medical Corporation reported Q1 2026 revenues of $15.96 million, reflecting a 21% increase year-over-year. The net loss narrowed significantly to $2.23 million from $4.07 million in the prior year. Management…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DERM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever